Alisertib
Myelofibrosis
Northwestern UniversitySmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 73/ 100
Competitive context
49 Active assets in the Myelofibrosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Anti-Thymoglobulin, Rabbit Fred Hutchinson Cancer Center | Phase 2 | BB |
CYCLOSPORIN A City of Hope Medical Center | Phase 2 | B |
Cyclophosphamide City of Hope Medical Center | Phase 3 | B |
Busulphan City of Hope Medical Center | Phase 2 | B |
Fludarabine Center for International Blood and Marrow Transplant Research | Phase 3 | B |
View all 50 →
Same molecule, other indications
Alisertib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →